Jun 13, 2023 / 09:40PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Great. Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, I cover the biotechnology sector at Goldman Sachs, and we're really pleased to have Vertex team with us today. So we have Reshma Kewalramani, who's the CEO and the President, as well as Stuart Arbuckle, who's the Chief Operating Officer of the company.
Thank you both for joining us.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPTo start here, maybe we could give a snapshot of the business, where it stands today, what we should anticipate in terms of strategy, commercial execution and the pipeline as we look towards the second half of the year and beyond?
Reshma Kewalramani - Vertex Pharmaceuticals Incorporated - CEO, President & Director
Sounds great. Well, first of all, it's very nice to see all of you in person as we are still all getting back to in-person meetings. Let me say a few words about